By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioTime, Inc. 

1301 Harbor Bay Parkway

Alameda  California  94502  U.S.A.
Phone: 510-521-3390 Fax: 510-521-3389


Key Statistics

Ownership: Public

Web Site: BioTime
Symbol: BTX

Company News
BioTime (BTX) Reports Pro Forma Gain On Deconsolidation Of OncoCyte Subsidiary 2/21/2017 6:13:06 AM
BioTime (BTX) Announces Closing Of Public Offering Of Common Stock 2/16/2017 6:57:23 AM
BioTime (BTX) Announces Pricing Of Public Offering Of Common Stock 2/10/2017 7:19:26 AM
BioTime (BTX) Announces Proposed Public Offering Of Common Stock 2/10/2017 6:51:32 AM
BioTime (BTX) Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., As General Counsel 2/7/2017 6:19:58 AM
BioTime (BTX) Expands Ophthalmology Portfolio With Global In-Licensing Agreement For Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center 2/6/2017 6:39:47 AM
BioTime (BTX) Release: Additional Data From Company’s OpRegen Clinical Trial in Dry-AMD to be Presented At ARVO 2017 1/19/2017 7:46:54 AM
BioTime (BTX) and Subsidiary Cell Cure Neurosciences Ltd. Establish Innovative Cell Therapy Manufacturing Center in Israel 1/3/2017 6:38:46 AM
BioTime (BTX) Achieves Patient Recruitment Milestone In Renevia Pivotal Trial 12/14/2016 10:10:16 AM
Positive Early Data From BioTime (BTX)’s Renevia Pivotal Trial Presented At IFATS Meeting 11/18/2016 11:46:16 AM